Ambea (AMBEA) Q2 2024 earnings summary

Executive summary

• Net sales grew by 6% year-over-year in Q2 2024 to SEK 3,519 million, with strong contributions from Vardaga, Stendi, and Nytida, while Altiden and Klara saw declines.

• EBITA increased by 42% to SEK 271 million, with margin improvement to 7.7% from 5.8% and net income more than doubling to SEK 95 million.

• Free cash flow rose by 24% in Q2 to SEK 458 million, supporting dividends, acquisitions, and share buybacks.

• Several bolt-on acquisitions completed, including Alpklyftan and Evus Omsorg, and a new share buyback program was launched.

• Ongoing investments in quality, leadership, and sustainability, with a focus on diversity and social responsibility.

Financial highlights

• EBITA margin improved to 7.7% in Q2 2024 (up from 5.8% in Q2 2023), and cash conversion remained above 100%.

• Free cash flow for Q2 was SEK 458 million, and for H1 SEK 872 million, both up year-over-year.

• Net debt/EBITDA (excl. IFRS 16) improved to 2.1x, well below the target of 3.25x.

• SEK 130 million distributed as dividends, SEK 72 million spent on acquisitions, and SEK 285 million on share buybacks in the last twelve months.

• Rolling twelve-month free cash flow post-tax reached SEK 840 million, up 37% from two quarters ago.

Outlook and guidance

• Continued organic growth and active M&A agenda expected to drive 8-10% growth target, with new unit openings planned for Nytida and Stendi.

• Profitability target of 9.5% adjusted EBITDA margin remains in focus, with current rolling twelve at 8.9%.

• Leverage at 2.1x EBITDA, below target, providing financial flexibility.

• Growth expected to continue through higher demand, new unit openings, price adjustments, and further acquisitions.

• Management expects continued profitability improvements, especially in Denmark, and sees further acquisition opportunities in H2.